When efficacious, PD-L1/PD-1 blockade therapies seem to counteract tumor-induced T cell dysfunctionality by interfering with PD-1 and PD-L1 signals, and by unleashing activating pathways (1, 56). This evidence concerns the gene CD274 and neoplasm.